All In Biotech

Drug Trial Radar · NCT00804193

Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis

A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Topical Suspension to Reference Ciclopirox Topical Suspension 0.77% in the Treatment of Tinea Pedis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 553 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

553

Actual

Start

Jun 2004

Primary completion

Dec 2004

Study completion Apr 2005

Sponsor

Lead sponsor
Padagis LLCIndustry
Sponsor type
Industry
First posted
Dec 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox Olamine Topical Suspension (Test Product) and Ciclopirox Topical Suspension 0.77% (Reference Product) in the treatment of subjects with tinea pedis, and to show the superiority of the active treatments over that of the vehicle.

Conditions

  • Tinea Pedis

Interventions

  • Ciclopirox Olamine Topical SuspensionDrug

    topical suspension

  • Ciclopirox Topical Suspension 0.77%-Reference ProductDrug

    topical suspension

  • Ciclopirox Olamine Topical Suspension-PlaceboDrug

    topical suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects in Each Treatment Group With Therapeutic SuccessTime frame: 6 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.